Welcome

Celebrating Over 75 Years Of Service

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

ADVOCACY UPDATES

Changes in MACRA

Macra 101 Image

Before the close of 2017, all physicians must take action to avoid the 4 percent cut that will be assessed in 2019 for not participating in the new Quality Payment Program (QPP) authorized by the Medicare Access and CHIP Reauthorization Act (MACRA).  Read More

CMS Announces Changes in MACRA Implementation Timeline. The Centers for Medicare and Medicaid Services (CMS) announced major changes to the implementation of the Medicare Access and CHIP Re-authorization (MACRA).
Read More

Upcoming Dates

07/15/20: Call for Scientific Papers
Learn more

09/11/20: Membership Application Deadline to be voted in at the 2020 Annual Meeting and to be eligible for AAOA Member Rate (FREE) for the 2020 Annual Meeting Learn more

12/01/20: Research Grant Cycle
Learn more

04/01/21: Fellow Exam Application Deadline
Learn more

06/01/21: Research Grant Cycle
Learn more

06/26/21: Membership Application Deadline to be eligible for AAOA Member rate for the 2021 Basic Course

EDUCATION

Allergy & ENT: Wait, Wait Don't Tell Me!, presented at the AAO-HNSF 2020 by Keith Andrew Sale, MD, Alpen A. Patel, MD, Glen Porter, MD, and Wesley D. Vander Ark, MD can be viewed here. It will be avialable through Friday, October 30, 2020.

Register Today for the 2020 AAOA Annual Meeting to earn up to 18.25 AMA PRA Category 1 Credit(s)TM for the live activity plus 8.75  AMA PRA Category 1 Credit(s)TM for the on demand content.

PLEASE ALLOW 24-48 HOURS FOR YOUR REGISTRATION TO BE PROCESSED FOR YOU TO RECEIVE THE LOGIN/ACCESS INSTRUCTIONS.

For those member and nonmembers who register for the AAOA 2020 Annual Meeting Oct 24-29 (live stream) before October 15th, you will be offered complimentary registration to participate in the AAO-HNSF “Comprehensive Otolaryngology Week” component of the AAO-HNSF 2020 Virtual Annual Meeting & OTO Experience. Access to the Comprehensive week – Each registrant will receive a welcome email with login instructions once the AAOA Annual Meeting Registration list is imported. The deadline to register to get the access is October 15th.

IFAR

IFAR Impact Factor: 2.454

aaoaf-ifar

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Now Available

Changes in Managing Practices

Mission

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2020 AAOA Annual Meeting
October 24-29, 2020
Virtual || Free For Members
Learn More and Register

AAOA Clinical Insights
Learn More and Register

USP 797 Online Module
Learn More and Register

2021 Basic Course in Allergy & Immunology
July 15-17 | Seattle, WA

News and Updates

Socio-Economic Committee Update May 2017

By AAOA Leadership Change is the only constant in life and medicine to borrow from…

read more
College Allergy Symptoms Treatment Back to Shcool

PRACTICE RESOURCES

AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More

PATIENT CORNER

Menu

Congress Moves Closer to Close the Books on FY 2018 Appropriations

In a span of 4 days, Congress passed legislation to fund the government through March 23 and the President released his FY 2019 budget proposal.  The release of the President’s budget request signals the official start of the FY 2019 appropriations cycle, but Congress now has until March 23 to finish the FY 2018 process.

The Bipartisan Budget Act of 2018 had three important pieces: it ended the government’s funding through March 23, raised the budget caps for FY 2018 and 2019, and addressed many important health provisions.  Of note, the legislation included several technical corrections to the Medicare Access and CHIP Reauthorization Act (MACRA) that the American Medical Association (AMA) supported.  The Quality Payment Program authorized by MACRA is beginning its second year, but there were several issues that the Centers for Medicare and Medicaid Services (CMS) could not address without statutory changes.  Last week Congress took action and made the following changes to the program:

  • Part B drug costs are now excluded from the calculation of Merit-Based Incentive Payment System (MIPS) bonuses and penalties. They had been excluded from the CMS quality programs that pre-dated MACRA.
  • The MACRA statute required the cost performance category, one of the four MIPS performance categories, to be weighted at 30% of a provider’s score in year 3 of the program. However, cost measures are not ready for adoption for many specialties.  The legislation provides that for years 2 through 5 of the program the cost performance category shall count for no less than 10% and no more than 30% of the MIPS score, providing CMS with additional flexibility in the implementation of the program.
  • For years 1 and 2 of MACRA, CMS set the performance threshold, which determines if a physician will receive no adjustment, a bonus, or a penalty, relatively low. MACRA required that in year 3 the performance threshold be set at the mean or median of MIPS scores.  This legislation provides CMS with more flexibility in setting the threshold, requiring only that the performance threshold increase from year 3 to year 5 of MIPS.
  • MACRA authorized the Physician Focused Payment Model Technical Advisory Committee (PTAC) to review proposals for physician-focused alternative payment models and make recommendations on their implementation to CMS. This law expands PTAC’s scope, allowing the panel to provide initial feedback and an explanation for the feedback on models.

Also of note, the legislation repealed the Independent Payment Advisory Board (IPAB) that was originally authorized by the Affordable Care Act.  The IPAB which was never empaneled was charged with making recommendations to reduce Medicare spending if growth hit a designated threshold.  There was bipartisan opposition to IPAB because the board would have had the power to implement cuts to the Medicare program if Congress did not act.

Many provisions in the bill, like the funding extension for the Community Health Centers and the National Health Service Corps, included spending that had to be offset.  To help defray these costs, Congress reduced the physician fee schedule conversion factor in 2019 from 0.5 to 0.25 percent.  This replaced the extension of the misvalued code target, which had been included as an offset in the original House bill.  The AMA estimated an extension of the misvalued code target would have reduced the conversion factor by 0.45 percent.

On February 12, President Trump released his proposed budget for Fiscal Year 2019 (FY19).  While Congress will ultimately decide what funding levels programs receive through its annual appropriations process, the budget does highlight top-level priorities of the Administration.  These priorities include funding to address the opioid epidemic, an emphasis on regulatory restructuring and reorganizing, and policies to address drug pricing.

The President recommended a $473 million increase for the Food and Drug Administration (FDA) with some of the funding targeted at speeding the generic drug approval process and combating the opioid epidemic.  The budget proposal also includes $33.8 billion in funding to the National Institutes of Health (NIH), which is an increase of $747 million.  But, since the NIH budget includes $750 million in new funding to address the opioids epidemic and $730 million associated with moving a handful of agencies from other HHS departments to the NIH, in reality, most Institutes and Centers within the NIH would face cuts.